Lithium Hexamethyldisilazide → N-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-4-methyl-3-[4-(3-methyl-3H-imidazol-4-yl)-pyrazol-1-yl]-benzamide

HRID 2109221ノート

反応式

HRID 2109221 の反応式
[NH2:1][C:2]1[C:3]([O:17][CH3:18])=[C:4]([NH:12][S:13]([CH3:16])(=[O:15])=[O:14])[CH:5]=[C:6]([C:8]([CH3:11])([CH3:10])[CH3:9])[CH:7]=1.[Li]CCCC.[Li+].C[Si]([N-][Si](C)(C)C)(C)C.C([O:36][C:37](=O)[C:38]1[CH:43]=[CH:42][C:41]([CH3:44])=[C:40]([N:45]2[CH:49]=[C:48]([C:50]3[N:51]([CH3:55])[CH:52]=[N:53][CH:54]=3)[CH:47]=[N:46]2)[CH:39]=1)C>C1COCC1.CO>[C:8]([C:6]1[CH:5]=[C:4]([NH:12][S:13]([CH3:16])(=[O:15])=[O:14])[C:3]([O:17][CH3:18])=[C:2]([NH:1][C:37](=[O:36])[C:38]2[CH:43]=[CH:42][C:41]([CH3:44])=[C:40]([N:45]3[CH:49]=[C:48]([C:50]4[N:51]([CH3:55])[CH:52]=[N:53][CH:54]=4)[CH:47]=[N:46]3)[CH:39]=2)[CH:7]=1)([CH3:10])([CH3:11])[CH3:9]

参加物

7

反応物 4

HCID 2733832Lithium HexamethyldisilazideHCID 10214710N-(3-amino-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamideHCID 588612804-methyl-3-[4-(3-methyl-3H-imidazol-4-yl)-pyrazol-1-yl]-benzoic acid ethyl esterHCID 178418339Butyllithium

生成物 1

HCID 21097201N-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-4-methyl-3-[4-(3-methyl-3H-imidazol-4-yl)-pyrazol-1-yl]-benzamide収率 33.6%

試薬・触媒・溶媒 2

HCID 887Methanol溶媒HCID 8028Tetrahydrofuran溶媒2 回

反応条件

温度
-78 °C

実験手順

A solution of N-(3-amino-5-tert-butyl-2-methoxy-phenyl)-methane-sulfonamide (81 mg, 0.261 mmol) in THF (4 mL) was stirred in a bath cooled to −78° C., and n-BuLi (0.22 mL, 0.548 mmol) was added slowly. The cold bath was removed, and the reaction was allowed to stir for 30 min. LHMDS (0.261 mmol) was then added slowly. The suspension was transferred dropwise to a stirring solution of compound 4-methyl-3-[4-(3-methyl-3H-imidazol-4-yl)-pyrazol-1-yl]-benzoic acid ethyl ester (81 mg, 0.261 mmol) in THF at 0° C. After 30 min cole MeOH was added and the mixture was partitioned between saturated NH4Cl and EtOAc, then extracted with EtOAc (3×). The organic combined extracts were washed with brine, dried over Na2SO4, filtered, and concentrated, and chromatographed (1% MeOH (with 5% NH4OH)/CH2Cl2 to 5% MeOH (with 5% NH4OH)/CH2Cl2) to afford N-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-4-methyl-3-[4-(3-methyl-3H-imidazol-4-yl)-pyrazol-1-yl]-benzamide (47 mg, 33%) as an orange foam: ESI MS m/z=537 [C27H32N6O4S+H]+.

後処理

  1. customThe cold bath was removed
  2. customthe mixture was partitioned between saturated NH4Cl and EtOAc
  3. extractionextracted with EtOAc (3×)
  4. washThe organic combined extracts were washed with brine
  5. dry with materialdried over Na2SO4
  6. filtrationfiltered
  7. concentrationconcentrated
  8. customchromatographed (1% MeOH (with 5% NH4OH)/CH2Cl2 to 5% MeOH (with 5% NH4OH)/CH2Cl2)

出典と根拠

ORDレコード
ord-143e69599c0b40b7a3d5a0ef9ef973d4
出典データセット
uspto-grants-2009_04
特許番号
US07514458B2

反応ノート

読み込み中…